Literature DB >> 3116428

Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin.

W A McGuire1, H H Yang, E Bruno, J Brandt, R Briddell, T D Coates, R Hoffman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3116428     DOI： 10.1056/NEJM198710153171606

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  16 in total

1.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

2.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

Review 3.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

4.  Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies.

Authors:  R Liblau; P Gajdos; F A Bustarret; R el Habib; J F Bach; E Morel
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

Review 5.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Authors:  S V Kaveri; G Dietrich; V Hurez; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

6.  Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin.

Authors:  M Toyoda; X Zhang; A Petrosian; O A Galera; S J Wang; S C Jordan
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

Review 7.  Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders.

Authors:  S A Schwartz
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

8.  Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies.

Authors:  G Dietrich; M D Kazatchkine
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

Review 9.  Harmful and beneficial antibodies in immune thrombocytopenic purpura.

Authors:  P A Imbach
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin.

Authors:  M J Evans; R Suenaga; N I Abdou
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.